Clinical Trial Update: RCT ALB for SA Cysticercosis [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating albendazole for subarachnoid cysticercosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subarachnoid Cysticercosis

Drugs mentioned

• Albendazole (ALBENDAZOLE)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Subarachnoid Cysticercosis | Phase 3 | Status: WITHDRAWN